Battling Malaria Strengthening the U.S. Military Malaria Vaccine Program (2006) / Chapter Skim
Currently Skimming:
Appendix A Vaccine Trials
Appendix A Vaccine Trials
Pages 81-94
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 81... ...
Appendix A Vaccine Trials 81
|
From page 82... ...
82 1992 1994 al., 2004 2000 2001 2004; 2005 et al., 1998 al., et al., al., al., al., 2 2000; al., et et et et et al., et et Phase References Herrington Gonzalez Le Wang Epstein Nardin Nardin Nardin Oliveira to Progressed 3/10 no and to but Yet) immunogenic CD4 T-cell responses cells Not cellular cells T 20)
|
From page 83... ...
83 1995 2005 al., 2005 al., et 1999 al., 2005 et al., et et al., et Audran Ramasamy Keitel Malkin Saul response; response cells, toxoid 14/32 T in forms instability) antibody antibody antibody antibody diphtheria both Antibody, interferon Good hypersensitivity to Good response Good to Low (vaccine No No WRAIR No No 720 19 FVO ISA conjugated two MSP1 and or toxoid of pastoris toxoid 720 (3D7 Pichia forms epitopes tetanus diphtheria MSP-3/alum MSP-1/MSP-2 to MSP-1/P30P2: allelic plus T-cell AMA-1C forms)
|
From page 84... ...
84 1991; 1979 1987 2002; 1994 al., al., al., 2005; et al., et et 2001 1987 al., et al., 1992 al., al., et from 1975; et et et al., et References Clyde, Herrington Hoffman Rieckmann Herrington Genton Lopez Ballou Fries Hoffman Volunteers Adult of bites 1000 protection > protected protection protected protected protected Challenge Results 95% after 1/3 No 1/6 1/3 2/11 of Experimental MIDRP Involvement University Maryland/ NMRC/ WRAIR No No WRAIR WRAIR NMRC/ WRAIR Using + Vaccines A wall toxoid repeats repeats/ cell 720 toxin CSP (282-383)
|
From page 85... ...
85 1996 2000 continued 1995 2005 1992 1995 al., 1997, 2001 al., al., al., al., al., et et al., al., et et et et et et Heppner Gordon Stoute 1998 Kester Walther Lawrence Sturchler Sturchler protected (0/11) and 2/8 single 2/7, protected and protected protected protected protected protected protection 0/6 1/8, 18/41 0/15 1.
|
From page 86... ...
86 al., 2006 2005; 2005 2005 et 2005; al., 2004; al., 2005; et al., al., al., 2006 et 2006 al., al., et et et et et References Wang Ockenhouse 1998 Dunachie Walsh Heppner, Heppner Heppner, Bejon Keating Webster vaccine vaccine in in vaccine compared compared compared protected protected increase RTS,S RTS,S increase protection RTS,S Results 0/31 1/35 No efficacy to Decreased efficacy to No efficacy to 20% MIDRP Involvement NMRC WRAIR Oxford/ WRAIR WRAIR WRAIR No AMA-1 AS02A 42 MVA SSP-2/TRAP, SSP-2/TRAP, Exp-1 SERA, fowlpox/MVA CSP, CSP, DNA/MVA LSA-3, MSP-1, AS02A/CSP MVA/RTS,S AS02A/SSP-2/TRAP AS02A/MSP-1 ME-TRAP CSP Vaccine Details MuStDO5: LSA-1, NYVAC-7: LSA-1, RTS,S or RTS,S RTS,S ME-TRAP and Continued virus A-2 of plasmids TABLE Type Vaccine DNA Recombinant Heterologous prime-boost
|
From page 87... ...
87 1990 2005; 1996 continued al., 2004 Challenge et 1994; al., 2004, 2001 é al., et al., al., al., et et et et Natural References Guiguemd Brown Sherwood Alonso Bojang Moorthy Using Trials (the effect 63%. no adults weak in to (see children effect clinical against adults effect Vaccine (Thailand, against in Faso, no with boosted year in no and malaria infection, 56% Gambia: protection malaria.
|
From page 88... ...
88 1995; 1995 1998; 1994; 1996 al., 2002 al., 1992; 1998; al., 1998; et 1999; 1994; 1997, et 1996; et 1993, al., al., 1995; al., 1994; al., al., al., al., et et al., al., et et et et et et al., al., et et et 'Alessandro References Genton Reber-Liske Acosta Alonso Amador Bojang D Leach Masinde Nosten Noya Sempertegui Urdaneta Valero vaccine)
|
From page 89... ...
89 H, in N, of e M, on F,J WR, The chal Ofori- SPf66 ainst Hurt African follow P, peptide inocula, hambre ag schem efficacy Espasa protecti 1992.
|
From page 91... ...
N, Hillier Soisson J Safety immunogenicity, of of Diseases research Development, W, liposomes.
|
From page 92... ...
92 ,J in ,P J, A of NA and 1999.
|
From page 93... ...
93 W, E, a .1996. laria DC, and ainst AN, in Ma eto nthetic letti Gross vaccine malaria ag mem- Zicker J, efficacy evalua- Group.
|
From page 94... ...
94 of D, G, AV, the Wirtz Matile rt uvant er 2005. P, Lozada vaccine, vaccine Taisne Science ng responses D, Journal adj ,immu- 864.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.